Inhaled medication corticosteroids

There are a number of corticosteroids that are used in pulmonology as inhalation medications. For rhinitis sprays may be used which also contain corticosteroids. Coricosteroids in these topical medications include beclometasone, fluticasone, mometa-sone and also budesonide. 

For the use of an inhaled medication (e.g., p2-agonists, corticosteroids, antivirals, cromolyn, etc.), it is crucial for the child and parents to understand the mechanism of the metered dose inhaler (MDI) or nebulizer, if used. The package insert should also be reviewed for information about the specific drug product. A decision may also need to be made as to whether a spacer may be needed for use with the medication canister. 

If more than one type of inhaled medication is taken it is important to take them in the correct order. Bronchodilating inhalers are used first to help open the airways. These are followed by corticosteroid inhalers. This ensures that the airways are open when the corticosteroid is administered, allowing as much of the dose as possible to be absorbed. 

Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication—does combining beta-agonists with corticosteroids improve compliance Eur Respir J 1994 7 504-509. 

The adverse effect profile of both oral and inhaled corticosteroids (ICS) has been and continues to be studied extensively. Although ICS are among the most frequently used inhaled medications for asthma and chronic obstructive pulmonary disease (COPD), they are associated with several adverse effects, which were recently reviewed in three Cochrane meta-analyses. 

Monitor for adverse events from medications, including candidiasis and dysphonia from inhaled corticosteroids. 

Upon discontinuation of inhaled corticosteroids some patients may experience deterioration in lung function and an increase in dyspnea and mild exacerbations it is reasonable to reinstitute the medication in these patients.25 Completion of ongoing clinical trials assessing mortality should help to clarify the role of corticosteroid treatment of COPD. 

The addition of a second long-term control medication to inhaled corticosteroid therapy is one recommended treatment option in moderate to severe persistent asthma. 

Concurrent corticosteroids While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast should not be abruptly substituted for inhaled or oral corticosteroids. 

Patients receiving salmeterol for asthma should normally also be receiving regular and adequate doses of an effective asthma controller medication, such as inhaled corticosteroid... 

When taken regularly (2-4 puffs two to four times daily) by patients with perennial (nonseasonal) asthma, both agents modestly but significantly reduce symptomatic severity and the need for bronchodilator medications. These drugs are neither as potent nor as predictably effective as inhaled corticosteroids. In general, young patients with extrinsic asthma are most likely to respond favorably. At present, the only way of determining whether a patient will respond is by a therapeutic trial for 4 weeks. The addition of nedocromil to a standard dose of an inhaled corticosteroid appears to improve asthma control. 

All patients were monosensitized with a persistence of symptoms despite action to eliminate mites and treatment with inhaled corticosteroids. Patients were included after an 8-week observation period which made it possible to determine the lowest effective dose of budesonide, with the performance of skin tests, lung function tests and a methacholine bronchial challenge test. The efficacy criteria were the medication and symptom scores, global assessment of the patient by the physician, skin tests and total IgE, lung function tests and the methacholine bronchial challenge test. 

In 1987 the xanthine derivative theophylline was the most commonly used medication in the treatment of asthma, followed by / 2-agonists, such as albuterol or ter-butaline, and inhaled corticosteroids, for example budesonide or flunisolide. Today, the most frequently used medication is inhaled / 2-agonists and it is expected that these therapy patterns have shifted toward greater use of inhaled corticosteroids [4, 5], Nevertheless, whether used alone or in combination with other therapies, corticosteroids do not consistently abrogate airway inflammation in patients with asthma common side effects associated with this type of drug are increased heart rate, nervousness, tremors, nasal irritation, nausea, and headaches [8, 10, 11],... 

Recent clinical guidelines suggest that a trial of a corticosteroid inhaler may be useful and should be made in bronchitic patients. Not all patients will benefit, but if the trial shows steroids to be effective they can be added to the patient s medication as maintenance therapy. 

HPI KG is a 39-year-old woman with asthma on fluticasone and albuterol complaining of SOB associated with exercise. Three months ago she started an aerobic exercise program that has been hampered by chest tightness and SOB shortly after she begins running. She admits to poor compliance with her corticosteroid inhaler and requests an oral medication to control her asthma symptoms. Her PMH is significant for mild, persistent asthma for 35 years and allergic rhinitis. Her medications include fluticasone and albuterol inhalers and fexofenadine. Pulmonary function tests (PFTs) reveal her forced expiratory volume in the first second (FEV,) = 89% of predicted. 

Omalizumab is indicated for adults and adolescents older than 12 years of age with allergies and moderate to severe persistent asthma. In this population, it has proven to be effective in reducing the dependency on inhaled and oral corticosteroids and in decreasing the frequency of asthma exacerbations. Omalizumab is not an acute bron-chodilator and should not be used as a rescue medication or as a treatment of status asthmaticus. 

---